Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
37 patients from the US, UK, Germany, Spain, and Italy who had locally advanced or metastatic EGFR-mutated NSCLC and had suffered from progressive disease while on osimertinib.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Patients with previously treated EGFR-mutated advanced NSCLC have significant symptom burden and emotional impacts of the disease. These patients would realistically expect a treatment that could improve their quality of life and delay the progression of their disease.
[BACKGROUND] Treatment effectiveness remains limited for patients with previously treated epidermal growth factor receptor (EGFR)-mutated advanced nonsmall cell lung cancer (NSCLC).
- 표본수 (n) 37
APA
Patel JD, Meng J, et al. (2026). Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study.. Clinical lung cancer, 27(3), 1-11. https://doi.org/10.1016/j.cllc.2026.02.003
MLA
Patel JD, et al.. "Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study.." Clinical lung cancer, vol. 27, no. 3, 2026, pp. 1-11.
PMID
41831391 ↗
Abstract 한글 요약
[BACKGROUND] Treatment effectiveness remains limited for patients with previously treated epidermal growth factor receptor (EGFR)-mutated advanced nonsmall cell lung cancer (NSCLC). Understanding patient unmet needs and treatment expectations can inform drug development decisions.
[METHODS] Qualitative interviews were conducted with n = 37 patients from the US, UK, Germany, Spain, and Italy who had locally advanced or metastatic EGFR-mutated NSCLC and had suffered from progressive disease while on osimertinib. Interview transcripts were analyzed following the content analysis technique. Participants also completed a questionnaire that included the EQ-5D-5 L and NSCLC-symptoms assessment questionnaire.
[RESULTS] All participants reported experiencing at least one respiratory symptom, such as fatigue or tiredness, with 97% reporting both. The most common impact on the participants' daily life activities was the incapacity to do any physical exertion (54%). All participants reported at least one emotional impact, most commonly mentioned as feeling scared/frightened or anxious/worried (62%), followed by feeling upset, unhappy, or depressed (57%). Improving quality of life was the most desired treatment outcome (76%), followed by slowing disease progression and remission (71% each). Most participants (81%) were willing to consider a new treatment despite the potential for side effects. From EQ-5D-5 L domains, "anxiety/depression" had the highest impact on participants' lives. The most severe symptoms based on NSCLC-symptoms assessment questionnaire were fatigue, pain, and dyspnea.
[CONCLUSION] Patients with previously treated EGFR-mutated advanced NSCLC have significant symptom burden and emotional impacts of the disease. These patients would realistically expect a treatment that could improve their quality of life and delay the progression of their disease.
[METHODS] Qualitative interviews were conducted with n = 37 patients from the US, UK, Germany, Spain, and Italy who had locally advanced or metastatic EGFR-mutated NSCLC and had suffered from progressive disease while on osimertinib. Interview transcripts were analyzed following the content analysis technique. Participants also completed a questionnaire that included the EQ-5D-5 L and NSCLC-symptoms assessment questionnaire.
[RESULTS] All participants reported experiencing at least one respiratory symptom, such as fatigue or tiredness, with 97% reporting both. The most common impact on the participants' daily life activities was the incapacity to do any physical exertion (54%). All participants reported at least one emotional impact, most commonly mentioned as feeling scared/frightened or anxious/worried (62%), followed by feeling upset, unhappy, or depressed (57%). Improving quality of life was the most desired treatment outcome (76%), followed by slowing disease progression and remission (71% each). Most participants (81%) were willing to consider a new treatment despite the potential for side effects. From EQ-5D-5 L domains, "anxiety/depression" had the highest impact on participants' lives. The most severe symptoms based on NSCLC-symptoms assessment questionnaire were fatigue, pain, and dyspnea.
[CONCLUSION] Patients with previously treated EGFR-mutated advanced NSCLC have significant symptom burden and emotional impacts of the disease. These patients would realistically expect a treatment that could improve their quality of life and delay the progression of their disease.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Male
- Female
- Lung Neoplasms
- Middle Aged
- ErbB Receptors
- Aged
- Quality of Life
- Mutation
- Qualitative Research
- 80 and over
- Adult
- Surveys and Questionnaires
- Acrylamides
- Aniline Compounds
- Indoles
- Pyrimidines
- Disease burden
- EGFR-mutated
- Interviews
- Lung cancer
- Metastatic
… 외 1개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.